We are live on ! Find out more
PMVP icon

PMV Pharmaceuticals

69 hedge funds and large institutions have $45.8M invested in PMV Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 20 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 10

21% more capital inflows, than outflows

Capital inflows: $13.5M | Capital outflows: $11.2M

6% more funds holding

Funds holding: 65 → 69 (+4)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1.02% less ownership

Funds ownership: 70.33% → 69.31% (-1%)

20% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 20

Holders
69
Holders Change
+4
Holders Change %
+6.15%
% of All Funds
0.84%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
16
Reduced
20
Closed
10
Calls
$108​K
Puts
–
Net Calls
+$108​K
Net Calls Change
+$41​K

PMVP Hedge Fund Activity: Q1 2026 in Review

69 of the 8,244 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q1 2026, worth a combined $45.8M — down 2% from $46.8M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new PMVP positions and 10 closed out — a net gain of 5 holders — while 16 added to existing stakes and 20 trimmed.

The largest buyer was Eversept Partners, opening a new position worth an estimated $2.99M. The largest seller was OrbiMed, exiting entirely with an estimated $6.22M sold.

  • 69 institutional investors held PMV Pharmaceuticals (PMVP) as of Q1 2026, up from 65 in Q4 2025.
  • Funds reported $45.8M of PMV Pharmaceuticals stock for Q1 2026, down 2% quarter-over-quarter.
  • 15 funds opened new PMV Pharmaceuticals positions in Q1 2026 and 10 closed out, a net change of +5 holders.
  • The largest PMV Pharmaceuticals buyer in Q1 2026 was Eversept Partners, an estimated $2.99M added.
  • The largest PMV Pharmaceuticals seller in Q1 2026 was OrbiMed, an estimated $6.22M sold.

Based on aggregated 13F filings for Q1 2026.